solute carrier family 2 member 10Genealiases: ATORS · ATS · GLUT10
Q-omics provides the consensus-scored SLC2A10 profile across patient tissues and cancer cell-line models. SLC2A10 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC2A10 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, SLC2A10 RNA expression shows 19,226 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where SLC2A10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC2A10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC2A10 survival associations across molecular data types. SLC2A10 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC2A10 RNA expression–survival associations across cancer types. High SLC2A10 expression shows unfavorable associations in UVM, MESO, LGG, LUAD and CESC, but favorable associations in SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC2A10 RNA expression.
This table summarizes SLC2A10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC2A10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC2A10 shows lower tumor expression in KICH and UCEC and higher tumor expression in BRCA, KIRP, PAAD and BLCA. The KICH box plot shows higher SLC2A10 RNA expression in normal versus tumor tissue (log2 FC = −1.787, t-test p < 0.001).
This table shows molecular features associated with SLC2A10 in patient tissues and cancer cell lines. In patient samples, SLC2A10 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC2A10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
